THLD MNTA AINV VHC RSO TORM DMND GMCR APKT AMSC
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We need one of those 70-80% droppers..been a while
Bounce coming?
CLF could get interesting if keeps dropping ..next test 16, then it gets ugly
LJPC was like 3 bucks in the summer..waaaaaaaaaaaaaaaa ..edit was some kind of r/s this year..1 for 50 I think..but still waaaaa
LJPC now up 60% a/h..sheesh
lol..man those 13,s haunting me
NXTM has a cancelled trade that would have been 80% drop..lol
http://www.nasdaq.com/symbol/nxtm/after-hours
bob putting on evil short hat,lol
FCEL earnings..6% dip
FuelCell Energy, Inc. EPS in line, beats on revenue
FuelCell Energy, Inc. (FCEL): FQ1 EPS of -$0.04 in line.Revenue of $44.43M (+22.1% Y/Y) beats by $0.96M
Howdy nitwit...when's da next doom???
Congrats again
Bernstein starts Aruba at Underperform, Ubiquiti at Outperform
As is the case with enterprise/carrier Wi-Fi rival Ruckus Wireless, Bernstein is launching coverage on Aruba Networks (ARUN) with an Underperform. The firm's PT is $14, 36% below current levels.On the other hand, Bernstein has started coverage on Ubiquiti (UBNT) with an Outperform and $65 PT (38% above today's close). Uiquiti also competes in the enterprise Wi-Fi space (its solutions are generally SMB-focused), but the majority of its sales come from other types of wireless networking systems.ARUN -0.7% AH
Maybe..kicking myself for not buying dip to 13..pffftt
DMND reports tomorrow a/h..for any "nuts" still holding
Last hand full of ICPT I had went off today 444.44..lmao..a few freebies from mid January swoon after its huge pop.
I surprised myself by holding this long..
Not real trading this afternoon..shaky connection on phone and no need to get stuck in something I can't trade out of..
Kinda boring as earnings season pretty wrapped up..but will start again in 3-4 weeks
Superb..I have been selling on spikes..last hand full went off today on 444.44 gtc order..lol
Congrats..they have a ROTH conference now at 5:30 and cc for trial news tomorrow at 8:30
Cut him some slack..aren't chicks forgiving like that? So call off airstrike..lol
ICPT 30 buck move today..double top?..anyone still holding ?
FTEK -16% a/h
Dunno..will check
LJPC big pop on trial news.La Jolla Pharmaceutical Company Reports Positive, Top-Line Results from Phase 2 Clinical Trial of GCS-100 in Chronic Kidney D...
Print
Alert
La Jolla Pharmaceutical Co. (NASDAQ:LJPC)
Primary Efficacy Endpoint of Improved Kidney Function Achieved
GCS-100 Well-tolerated
Conference Call and Webcast at 8:30 AM Eastern Time on Tuesday, March 11
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”) today announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease (CKD). The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. Specifically, a dose of 1.5 mg/m2 led to a statistically significant (p=0.045) increase in estimated glomerular filtration rate (eGFR) compared to placebo between baseline and end of treatment. At the 30 mg/m2 dose, there was no statistically significant difference.
Key secondary endpoints were also met, and the effect on circulating galectin-3 levels was consistent with the effect on eGFR. For the 1.5 mg/m2 dose, there was a statistically significant (p=0.067) reduction in circulating levels of galectin-3, while there was no significant difference at the 30 mg/m2 dose level. Galectin-3 is the molecular target of GCS-100 and has been shown to be a mediator of tissue fibrosis. Potassium, uric acid and blood urea nitrogen (BUN) all improved at the 1.5 mg/m2 dose level.
GCS-100 was well-tolerated. Out of 121 patients enrolled, 117 completed treatment, including all 41 patients treated at the 1.5 mg/m2 dose. There were no serious adverse events (SAEs) in the 1.5 mg/m2 dose group compared to two in the placebo group and two in the 30 mg/m2 group. All SAEs were deemed by the investigators as not drug-related.
“Chronic kidney disease is an enormous and growing medical problem worldwide. A disease-modifying agent that could slow and potentially reverse the tissue fibrosis that is a hallmark of this disease would be a welcome advance in the field and could have a major impact on patients’ lives,” stated Pablo E. Pergola, M.D., Ph.D., Director of the Clinical Advancement Center subsidiary of Renal Associates P.A. and Clinical Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio. “Our experience with GCS-100 in this trial was very encouraging, and my patients tolerated the therapy well.”
“We want to thank the patients who volunteered for this study and our excellent group of investigators for their hard work completing this Phase 2 trial in a timely fashion. We are obviously delighted with the results,” said George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla Pharmaceutical. “We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role.”
About the GCS-100 Phase 2 CKD Study
This Phase 2 study was a blinded, multi-center, randomized clinical trial that enrolled 121 patients with Stage 3b or 4 CKD. Patients were randomly assigned 1:1:1 to treatment with placebo, 1.5 mg/m2 of GCS-100, or 30 mg/m2 of GCS-100. Patients received the assigned treatment weekly for eight weeks followed by a four-week follow-up period. According to the pre-defined protocol and statistical analysis plan, the primary endpoint was reached if the change in eGFR from baseline to the end of treatment in either GCS-100 dose group compared to placebo had a significance of less than 10% (p value of < 0.10). The t-test was the primary statistical test used for comparison between groups unless a significant covariate was found and then the ANCOVA test was employed.
A Phase 2 extension study, in which patients from the placebo-controlled Phase 2 trial are being re-randomized to receive continued weekly treatments for up to a total of one year, is ongoing.
The protocols for the Phase 2 study reported on here (GCS-100-CS-4002) and the ongoing Phase 2 extension study (GCS-100-CS-4003) can be found on the Company’s website (www.ljpc.com).
Webcast and Conference Call
The Company will be presenting at the 26th Annual ROTH Conference at 5:30 PM Eastern Time/2:30 PM Pacific Time today. A live webcast and slide presentation will be made available through the Company’s website (www.ljpc.com), which also can be accessed by clicking here.
The Company will hold an investor conference call and webcast at 8:30 AM Eastern Time/5:30 AM Pacific Time on Tuesday, March 11, 2014. You can participate on the call by either dialing (877) 359-9508 pin: 11631205 or clicking here for the webcast.
About Chronic Kidney Disease
Ch
Life has tons of "IF's"..aw long as we get up in the morning..everything else is a bonus
Absolutely insane movers..facepalm for me
Well hopefully NBG will be rewarding..but u have enough..never put all eggs in one basket
Still big position? Or ludricous size?
WLT sucking ..a few 9.35s for shiggles
WTW decent unSUCKage today
I guess news on debt rework..plus iron ore tankage on China stuff..weak iron ore means weak steel demand and that means weak met coal demand..my 2 cents
A few 9.35 in case it wants to unTURD
evil shorts?lol..some profit taking I guess
Flexion picks up two more bullish ratings
Wells Fargo initiates coverage of Flexion Theapeutics (FLXN) with an Outperform rating with a price target of $24 - $26 citing positive Phase 2 trial results of its lead product, FX006, a sustained-release injectable steroid for osteoarthritis pain.
Needham & Co. initiates coverage with a Buy rating and $26 price target.
The stock debuted on February 12.
Shares currently exchange hands at $19.
gravity will not be denied..unless its TSLA,lol
those might have been mine,lol
NFLX dumped 15,TSLA 10
WUBA off$5
Stink bids on a few march strikes..and would like cheapies on july and sept 7 or 8s